Business Model

Sinclair Pharma enters the healthcare product cycle after the initial high-risk research phase. The company focuses on acquiring innovative products that are late in the development cycle, have intellectual property (IP) protection, or can be IP protected. Sinclair targets products that are undervalued, and applies regulatory expertise to gain registration for these products so that their commercial potential can be unlocked.

The products are then commercialised in two ways:

	Sinclair has its specialist sales and marketing operations in selected major territories and selected therapeutic areas. There are now sales and marketing operations in the UK (Ashbourne Pharmaceuticals Ltd), Italy (Sinclair Srl), and France, Spain and Portugal (CSDermatologie).
	Sinclair has built up a network of reputable marketing partners that spans 82 countries. Strong sales growth has been seen through working closely with these companies, and this network is still expanding.

Operations

Sinclair Pharma now has employees based at offices in Godalming (Surrey, UK), Milan (Italy), Dallas (TX, USA), Lebanon (NJ, USA), Gothenburg and Stockholm (Sweden). These staff are supported by a global network of consultants and advisors. It has sales forces in Italy, France, the UK, Spain and Portugal.

To contact Sinclair Pharma, click here.

Marketing Partners

Sinclair has a network of reputable marketing partners in 82 countries. For more information please click here.

Sales and marketing

The first territory in which Sinclair has established its own direct sales and marketing operation was Italy, where Sinclair acquired the company Euroderm in 2005. This name has now been changed to Sinclair Srl, and the company is already enjoying good sales with a wide range of products. Atopiclair, its first product from the Sinclair pipeline, was launched in September 2005.

In March 2006, Sinclair acquired CS Dermatologie, one of France's most successful dermatology companies.  CSDermatologie sells a range of prescription, over the counter and dermo-cosmetic products in France, Spain and Portugal.  While part of the Sinclair group, products are sold under the established brand name CS Dermatologie.  

In September 2006, Sinclair acquired Ashnourne Pharmaceuticals Ltd, a UK-based sales and marketing company that specialises in targeting dispensing doctors.  Ashbourne has a reputable salesforce in the UK.

Sinclair is planning to expand its own sales and marketing operations in the remaining major EU territories and the US. In this way, the company can access the higher margins of the sales and marketing end of the business and have a closer control of its brands in the major pharmaceutical markets.